Autres langues AstraZeneca PLC Boerse Muenchen

Actions

ZEGA

US0463531089

Produits pharmaceutiques

Temps réel Boerse Muenchen			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		-.--%	-1,26%

09/09	Les actions britanniques chutent à leur plus bas niveau en plus d'un mois, les prix du pétrole ravivant les craintes inflationnistes	RE
09/09	La Bourse de Stockholm recule dans un marché baissier généralisé, l'indice OMXS30 perd 1,6 %	FW

Autres langues

09/09	UK stocks drop to over one-month low as oil prices fuel inflation worries
09/09	Los datos del fármaco para la EPOC de AstraZeneca impulsarán las perspectivas de ventas -- Market Talk
09/09	HEALTH ROUNDS-AstraZeneca drug reduces lung disease flare-ups in late-stage trials
09/09	RBC prefers Astra to GSK; HSBC cuts Burberry
09/09	RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point
08/09	Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
08/09	Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
08/09	AstraZeneca Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival And Progression-Free Survival With IMFINZI Plus Tarlatamab In First-Line Extensive-Stage Small Cell Lung Cancer
08/09	Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer
08/09	Correction to AstraZeneca Article
08/09	Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study
08/09	AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study
08/09	Astrazeneca erzielt Studienerfolg mit COPD-Medikament
08/09	AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
08/09	Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial
08/09	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
08/09	AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials
08/09	AstraZeneca Demonstrates Statistically Significant Reduction In COPD Exacerbations With Tozorakimab In OBERON And TITANIA Phase III Trials
08/09	AstraZeneca's Tozorakimab Shows Statistically Significant Efficacy in Late-stage Trials
08/09	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
08/09	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
08/09	Guardant Health's Breast Cancer Diagnostic Approved by US FDA
08/09	Jefferies raises Autotrader and Rightmove
08/09	Clever Culture Systems builds commercial momentum with global pharma expansion
07/09	Global markets live: Amazon, Lockheed Martin, Novartis, Audi, Eni…